{
    "2020-10-19": [
        [
            {
                "time": "2023-03-15",
                "original_text": "AbbVie Submits Anti-Inflammatory Drug Rinvoq for FDA, Europe Approval for Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Rinvoq",
                        "FDA",
                        "Europe",
                        "Atopic Dermatitis",
                        "Approval"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Analyst Report: AbbVie Inc.",
                "features": {
                    "keywords": [
                        "Analyst Report",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQâ„¢ (upadacitinib) in Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "RINVOQ",
                        "FDA",
                        "EMA",
                        "Atopic Dermatitis",
                        "Regulatory Applications"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod",
                "features": {
                    "keywords": [
                        "Roche",
                        "AbbVie",
                        "Leukemia",
                        "Drug",
                        "Venclexta",
                        "FDA",
                        "Approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "AbbVie Announces Commencement of Registered Exchange Offers",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Registered Exchange Offers",
                        "Announcement"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}